A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 242, Issue 9, 2004, Pages 767-770

  Manni, Gianluca ^a   Centofanti, Marco ^a,b   Parravano, Mariacristina ^a   Oddone, Francesco ^a   Bucci, Massimo G ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST; TIMOLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EYE PHOTOGRAPHY; EYELASH; FEMALE; HEADACHE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN PIGMENTATION;

ADULT; AGED; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; SAFETY; SINGLE-BLIND METHOD; TIMOLOL; TREATMENT OUTCOME;

EID: 6344231803     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-004-0866-2     Document Type: Article

References (25)

1. Batterbury M, Harding SP (1992) Long-term drift and timolol therapy: possible role for pulsed therapy. Int Ophthalmol 16(4-5):321-324
2. Brandt JD, VanDenburgh AM (2001) Comparison of once or twice daily bimatoprost with twice daily timolol in patients with elevated IOP. Ophthalmol 108(6):1023-1032
3. Bron AM, Denis P (2001) Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol. Acta Ophthalmol Scand 79(3): 289-293
4. Brubaker RF (2001) Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol 45 [Suppl 4]:S347-351. Review
5. Brubaker RF, Schoff EO (2001) Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 131:19-24
6. Camras CB (2002) Bimatoprost vs. timolol. Ophthalmology 109(4):627-628; discussion 628-629
7. Collaborative Normal Tension Glaucoma Study Group (1998) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126:487-497
8. Gandolfi S, Simmons ST (2001) Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 18:3
9. Gordon MO, Beiser JA (2002) The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120:701-713
10. Heijl A, Leske MC for the Early Manifest Glaucoma Trial Group (2002) Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120:1268-1279
11. Higginbotham EJ, Schuman JS (2002) One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 120:10
12. Laibovitz RA, VanDenburgh AM (2001) Comparison of the ocular hypotensive lipid AGN 192024 with timolol. Arch Ophthalmol 119(7):994-1000
13. Lama PJ (2002) Systemic adverse effects of beta-adrenergic blockers: an evidence based assessment. Am J Ophthalmol 134(5):749-760
14. Lichter PR (2002) Expectation of clinical trials. Results of Early Manifest Clinical Trial. Arch Ophthalmol 120:10
15. Noecker RS, Dirks MS (2003) A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 135(1):55-63
16. O'Connor DJ, Martone JF (2002) Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 133(6):836-837
17. Pisella PJ, Pouliquen P (2002) Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 86(4):418-423
18. Sharif NA, Williams GW (2001) Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol 432(2-3):211-213
19. Shedden A, Laurence J (2001) Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. Clin Ther 23(3):440-450
20. Sherwood M, Brandt J (2001) Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 45 [Suppl 4] May
21. Soltau JB, Zimmerman TJ (2002) Changing paradigms in the medical treatment of glaucoma. Surv Ophthalmol 47 [Suppl 1]:S2-5
22. Sugimoto M, Sugimoto M (2002) Quantitative analysis of eyelash lengthening following topical latanoprost therapy. Can J Ophthalmol 37(6):342-345
23. The AGIS Investigators (2000) The Advanced Glaucoma Intervention Study (AGIS). VII. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130:429-440
24. The Pharmacology of Bimatoprost (Lumigan) (2001) Surv Ophthalmol 45 [Suppl 4]
25. Zhang WY, Po AL (2001) Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 85:983-990